NorthRock Partners LLC Increases Stock Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

NorthRock Partners LLC lifted its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 209.6% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 4,535 shares of the medical equipment provider's stock after purchasing an additional 3,070 shares during the quarter. NorthRock Partners LLC's holdings in Intuitive Surgical were worth $2,367,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. Bennett Selby Investments LP boosted its position in shares of Intuitive Surgical by 3.9% during the fourth quarter. Bennett Selby Investments LP now owns 449 shares of the medical equipment provider's stock valued at $234,000 after buying an additional 17 shares during the last quarter. Onefund LLC boosted its position in shares of Intuitive Surgical by 1.9% during the fourth quarter. Onefund LLC now owns 947 shares of the medical equipment provider's stock valued at $494,000 after buying an additional 18 shares during the last quarter. LVW Advisors LLC boosted its position in shares of Intuitive Surgical by 1.3% during the fourth quarter. LVW Advisors LLC now owns 1,448 shares of the medical equipment provider's stock valued at $756,000 after buying an additional 19 shares during the last quarter. Wesbanco Bank Inc. boosted its position in shares of Intuitive Surgical by 1.6% during the fourth quarter. Wesbanco Bank Inc. now owns 1,216 shares of the medical equipment provider's stock valued at $635,000 after buying an additional 19 shares during the last quarter. Finally, Journey Strategic Wealth LLC boosted its position in shares of Intuitive Surgical by 1.9% during the fourth quarter. Journey Strategic Wealth LLC now owns 1,039 shares of the medical equipment provider's stock valued at $542,000 after buying an additional 19 shares during the last quarter. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, EVP Brian Edward Miller sold 8,900 shares of the company's stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $485.07, for a total value of $4,317,123.00. Following the completion of the transaction, the executive vice president now directly owns 5,758 shares in the company, valued at approximately $2,793,033.06. This represents a 60.72% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Myriam Curet sold 2,401 shares of the business's stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $581.00, for a total value of $1,394,981.00. Following the completion of the sale, the executive vice president now directly owns 353 shares of the company's stock, valued at approximately $205,093. This trade represents a 87.18% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 32,700 shares of company stock worth $16,865,621 over the last ninety days. 0.70% of the stock is owned by corporate insiders.

Intuitive Surgical Stock Up 0.6%

Shares of NASDAQ:ISRG traded up $3.32 during midday trading on Friday, reaching $563.60. 1,422,176 shares of the company traded hands, compared to its average volume of 1,640,855. Intuitive Surgical, Inc. has a 12 month low of $393.98 and a 12 month high of $616.00. The firm's fifty day moving average price is $505.22 and its two-hundred day moving average price is $536.45. The firm has a market capitalization of $202.00 billion, a price-to-earnings ratio of 87.93, a price-to-earnings-growth ratio of 5.85 and a beta of 1.70.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last posted its earnings results on Tuesday, April 22nd. The medical equipment provider reported $1.81 EPS for the quarter, topping the consensus estimate of $1.71 by $0.10. Intuitive Surgical had a return on equity of 14.55% and a net margin of 27.81%. The business had revenue of $2.25 billion during the quarter, compared to analysts' expectations of $2.19 billion. During the same period in the previous year, the business earned $1.50 earnings per share. Analysts forecast that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts recently commented on ISRG shares. Evercore ISI dropped their price target on Intuitive Surgical from $510.00 to $470.00 and set an "in-line" rating on the stock in a report on Wednesday, April 23rd. UBS Group boosted their target price on Intuitive Surgical from $500.00 to $560.00 and gave the company a "neutral" rating in a research note on Monday, January 27th. CICC Research started coverage on Intuitive Surgical in a research note on Monday, January 27th. They issued a "neutral" rating and a $550.00 target price on the stock. Leerink Partners boosted their target price on Intuitive Surgical from $490.00 to $548.00 in a research note on Monday, January 27th. Finally, Wells Fargo & Company boosted their target price on Intuitive Surgical from $630.00 to $687.00 and gave the company an "overweight" rating in a research note on Friday, January 24th. Five investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $598.95.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.